• Mon, August 8, 2022

Madhu Kumar Maintained (ARWR) at Strong Buy with Increased Target to $65 on, Aug 8th, 2022

Madhu Kumar of Goldman Sachs, Maintained "Arrowhead Pharmaceuticals, Inc." (ARWR) at Strong Buy with Increased Target from $58 to $65 on, Aug 8th, 2022.

Madhu has made no other calls on ARWR in the last 4 months.



There are 5 other peers that have a rating on ARWR. Out of the 5 peers that are also analyzing ARWR, 1 agrees with Madhu's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Mani Foroohar of "SVB Leerink" Maintained at Hold with Decreased Target to $35 on, Wednesday, May 11th, 2022


These are the ratings of the 4 analyists that currently disagree with Madhu


  • Patrick Trucchio of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $110 on, Friday, June 3rd, 2022
  • Edward Tenthoff of "Piper Sandler" Maintained at Buy with Decreased Target to $72 on, Wednesday, May 11th, 2022
  • Joel Beatty of "Baird" Upgraded from Hold to Buy and Decreased Target to $60 on, Wednesday, May 11th, 2022
  • Keay Nakae of "Chardan Capital" Maintained at Strong Buy with Decreased Target to $80 on, Wednesday, May 11th, 2022